Table 1.

Minimal-inhibitory concentrations of oxadiazoles against Gram-positive bacteria, as determined by the microdilution MIC method.

Bacterial strains	2h	3	4	vancomycin	linezolid
S. aureus ATCC 29213a	2	4	2	1	2
S. aureus ATCC 27660 b	2	4	2	2	1
S.aureus N315 (NRS70)b	2	2	1	1	1
S. aureus NRS100 (COL)b	2	2	2	2	1
S. aureus NRS119c	2	2	1	1	32
S. aureus NRS120c	2	2	2	1	32
S. aureus VRS1d	2	2	1	64	1
S. aureus VRS2e	2	2	1	32	1
S. epidermidis ATCC 35547	2	2	1	4	0.5
S. haemolyticus ATCC 29970	2	4	2	4	1
B. licheniformis ATCC 12759	2	8	2	0.5	0.5
E. faecalis ATCC 29212a	2	8	4	2	1
E. faecalis 201 (Van S)f	2	4	4	1	1
E. faecalis 99 (Van R)g	2	4	4	128	1
E. faecium 119-39A (Van S)f	1	1	1	0.5	1
E. faecium 106 (Van R)g	2	2	1	128	1
E. faecium NCTC 7171	2	2	1	0.5	1

^aA quality-control strain to monitor accuracy of MIC testing;

^bmecA positive, resistant to methicillin, oxacillin, and tetracycline; susceptible to vancomycin and linezolid;

^cmecA positive, resistant to ciprofloxacin, gentamicin, oxacillin, penicillin, and linezolid;

^dvancomycin-resistant MRSA (vanA) clinical isolate from Michigan;

^evancomycin-resistant MRSA (vanA) clinical isolate from Pennsylvania;

^fvancomycin-susceptible clinical isolate;

^gvancomycin-resistant clinical isolate.

^hreproduced from O Daniel et al [9].